Format

Send to

Choose Destination
Nat Methods. 2008 Aug;5(8):673-8. doi: 10.1038/nmeth.1232.

Engineering GPCR signaling pathways with RASSLs.

Author information

1
Gladstone Institute of Cardiovascular Disease, 1650 Owens Street, San Francisco, California 94158, USA. bconklin@gladstone.ucsf.edu

Abstract

We are creating families of designer G protein-coupled receptors (GPCRs) to allow for precise spatiotemporal control of GPCR signaling in vivo. These engineered GPCRs, called receptors activated solely by synthetic ligands (RASSLs), are unresponsive to endogenous ligands but can be activated by nanomolar concentrations of pharmacologically inert, drug-like small molecules. Currently, RASSLs exist for the three major GPCR signaling pathways (G(s), G(i) and G(q)). We review these advances here to facilitate the use of these powerful and diverse tools.

PMID:
18668035
PMCID:
PMC2703467
DOI:
10.1038/nmeth.1232
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center